BAM
BLUE

Byrne Asset Management’s bluebird bio BLUE Stock Holding History

Byrne Asset Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-400
Closed -$11.2K – 532
2023
Q4 		$11.2K Buy
+400
New +$24.4K 0.01% 346
2023
Q2 		– Sell
-145
Closed -$9K – 589
2023
Q1 		$9K Buy
+145
New +$16.6K 0.01% 392

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Byrne Asset Management's BLUE Position: Q1 2024 in Review

Byrne Asset Management sold out of bluebird bio (BLUE) in Q1 2024, closing a stake of 400 shares — an estimated $11.2K sold.

Byrne Asset Management first reported a position in BLUE in Q1 2023 and held it in 2 quarters. The position peaked at $11.2K in Q4 2023. 158 funds tracked by Wall St. Rank hold BLUE as of Q1 2024.

  • Byrne Asset Management reported no remaining bluebird bio position as of Q1 2024 after selling out during the quarter.
  • Byrne Asset Management sold 400 bluebird bio shares in Q1 2024, an estimated $11.2K.
  • Byrne Asset Management first reported a position in bluebird bio in Q1 2023 and held it in 2 quarters.
  • Byrne Asset Management's bluebird bio position peaked at $11.2K in Q4 2023.
  • 158 funds tracked by Wall St. Rank held bluebird bio as of Q1 2024.

Based on Byrne Asset Management's 13F filing for Q1 2024, filed 22 Apr 2024.